{"id":"tnm001","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TNM001 is designed as a trispecific monoclonal antibody that targets multiple immune regulatory pathways simultaneously. By engaging three distinct molecular targets on immune cells and/or tumor cells, it aims to overcome immune suppression more effectively than bispecific or monospecific approaches, potentially enhancing T-cell activation and proliferation against cancer cells.","oneSentence":"TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:10.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06710925","phase":"PHASE3","title":"A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2024-11-28","conditions":"Respiratory Syncytial Virus Infections","enrollment":315},{"nctId":"NCT06083623","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2023-09-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":2282},{"nctId":"NCT05630573","phase":"PHASE1, PHASE2","title":"A Study of TNM001 in Chinese Healthy Preterm and Term Infants","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-10-25","conditions":"Respiratory Syncytial Virus Infections","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TNM001","genericName":"TNM001","companyName":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","companyId":"zhuhai-trinomab-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}